{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:56:55Z","timestamp":1792655815335,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10549-021-06387-1","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T08:06:27Z","timestamp":1631865987000},"page":"357-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer"],"prefix":"10.1007","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8897-4229","authenticated-orcid":false,"given":"Hannah","family":"Van Belle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-7191","authenticated-orcid":false,"given":"Sara A.","family":"Hurvitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7748-1891","authenticated-orcid":false,"given":"Peter J.","family":"Gilbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-7837","authenticated-orcid":false,"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"6387_CR1","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agneese D, Allison KH, Anderson BO et al (2021) Breast Cancer NCCN Guidelines Version 1.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed 23 Jan 2021"},{"issue":"14","key":"6387_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M-C, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay M-A, Riva A, Crown J (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273\u20131283. https:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"key":"6387_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-404","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. https:\/\/doi.org\/10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"issue":"10","key":"6387_CR4","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. https:\/\/doi.org\/10.1002\/cncr.21847","journal-title":"Cancer"},{"issue":"3","key":"6387_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers H, Reiser M (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77(3):221\u2013240. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.02.002","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"6387_CR6","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/sj.bjc.6601279","volume":"89","author":"Leonard RCF, Miles D, Thomas R, Nussey F, on behalf of the UKBCNAG","year":"2003","unstructured":"Leonard RCF, Miles D, Thomas R, Nussey F, on behalf of the UKBCNAG (2003) Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 89(11):2062\u20132068. https:\/\/doi.org\/10.1038\/sj.bjc.6601279","journal-title":"Br J Cancer"},{"issue":"1","key":"6387_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10549-017-4646-1","volume":"169","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu Q, Wu XC, Hsieh MC, Loch M, Chen VW, Fontham E, Ferguson T (2018) Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative. Breast Cancer Res Treat 169(1):175\u2013187. https:\/\/doi.org\/10.1007\/s10549-017-4646-1","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"6387_CR8","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","volume":"90","author":"DR Budman","year":"1998","unstructured":"Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E 3rd (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90(16):1205\u20131211. https:\/\/doi.org\/10.1093\/jnci\/90.16.1205","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"6387_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/nejm199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164\u2013170. https:\/\/doi.org\/10.1056\/nejm199107183250305","journal-title":"N Engl J Med"},{"issue":"21","key":"6387_CR10","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/jco.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167. https:\/\/doi.org\/10.1200\/jco.2006.08.8823","journal-title":"J Clin Oncol"},{"issue":"10","key":"6387_CR11","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475\u20132484. https:\/\/doi.org\/10.1093\/annonc\/mdt226","journal-title":"Ann Oncol"},{"issue":"2","key":"6387_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2014","unstructured":"Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z (2014) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 23(2):525\u2013545. https:\/\/doi.org\/10.1007\/s00520-014-2457-z","journal-title":"Support Care Cancer"},{"key":"6387_CR13","doi-asserted-by":"publisher","first-page":"007913","DOI":"10.1002\/14651858.CD007913.pub2","volume":"10","author":"P Renner","year":"2012","unstructured":"Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M (2012) Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 10:007913. https:\/\/doi.org\/10.1002\/14651858.CD007913.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"6387_CR14","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Baser O, Kutikova L, Page JH, Barron R (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 23(11):3131\u20133140. https:\/\/doi.org\/10.1007\/s00520-015-2686-9","journal-title":"Support Care Cancer"},{"key":"6387_CR15","unstructured":"Becker PS, Griffiths EA, Alwan L, Bachiashvili K, Brown A, Cool R et al (2020) National Comprehensive Cancer Network (NCCN) Guidelines for Supportive Care: Hematopoietic Growth Factors - version 2.2020. NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#supportive. Accessed 24 Oct 2020"},{"issue":"9","key":"6387_CR16","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","volume":"29","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Yau L, Nakov R, Krendyukov A (2018) Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol 29(9):1903\u20131910. https:\/\/doi.org\/10.1093\/annonc\/mdy311","journal-title":"Ann Oncol"},{"issue":"6","key":"6387_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2165\/11590130-000000000-00000","volume":"30","author":"BR Hirsch","year":"2012","unstructured":"Hirsch BR, Lyman GH (2012) Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics 30(6):497\u2013511. https:\/\/doi.org\/10.2165\/11590130-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"28","key":"6387_CR18","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/jco.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/jco.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"4","key":"6387_CR19","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases Society of America. Clin Infect Dis 52(4):e56-93. https:\/\/doi.org\/10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"issue":"suppl 5","key":"6387_CR20","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"issue":"1","key":"6387_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Lago LD, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"issue":"19","key":"6387_CR22","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1200\/jco.2006.09.9994","volume":"25","author":"BP Coudert","year":"2007","unstructured":"Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, Priou F, Gligorov J, Martin X, Trillet-Lenoir V, Weber B, Bleuse JP, Vasseur B, Serin D, Namer M (2007) Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 25(19):2678\u20132684. https:\/\/doi.org\/10.1200\/jco.2006.09.9994","journal-title":"J Clin Oncol"},{"issue":"4","key":"6387_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2217\/bmt.14.22","volume":"3","author":"P Gilbar","year":"2014","unstructured":"Gilbar P, McPherson I, Sorour N, Sanmugarajah J (2014) High incidence of febrile neutropenia following adjuvant breast chemotherapy with docetaxel, carboplatin and trastuzumab. Breast Cancer Manag 3(4):327\u2013333. https:\/\/doi.org\/10.2217\/bmt.14.22","journal-title":"Breast Cancer Manag"},{"issue":"7","key":"6387_CR24","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"issue":"7","key":"6387_CR25","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"6387_CR26","unstructured":"Barendregt JJ (2016) MetaXL version 5.3. https:\/\/www.epigear.com\/index_files\/metaxl.html. Accessed 20 Dec 2020"},{"issue":"9","key":"6387_CR27","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cort\u00e9s J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278\u20132284. https:\/\/doi.org\/10.1093\/annonc\/mdt182","journal-title":"Ann Oncol"},{"issue":"2","key":"6387_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1703643","journal-title":"N Engl J Med"},{"issue":"1","key":"6387_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19(1):115\u2013126. https:\/\/doi.org\/10.1016\/s1470-2045(17)30716-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"6387_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-020-05524-6","volume":"180","author":"N Masuda","year":"2020","unstructured":"Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M (2020) A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res Treat 180(1):135\u2013146. https:\/\/doi.org\/10.1007\/s10549-020-05524-6","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6387_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10549-011-1862-y","volume":"131","author":"G Rocque","year":"2012","unstructured":"Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME (2012) Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Res Treat 131(2):713\u2013721. https:\/\/doi.org\/10.1007\/s10549-011-1862-y","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"6387_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-013-2582-2","volume":"139","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Tomita D, Whittaker S, Crawford J (2013) A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat 139(3):863\u2013872. https:\/\/doi.org\/10.1007\/s10549-013-2582-2","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6387_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4048\/jbc.2014.17.4.356","volume":"17","author":"P Jitawatanarat","year":"2014","unstructured":"Jitawatanarat P, O\u2019Connor TL, Kossoff EB, Levine EG, Chittawatanarat K, Ngamphaiboon N (2014) Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer. J Breast Cancer 17(4):356\u2013362. https:\/\/doi.org\/10.4048\/jbc.2014.17.4.356","journal-title":"J Breast Cancer"},{"issue":"1","key":"6387_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-016-4098-z","volume":"162","author":"I Echavarria","year":"2017","unstructured":"Echavarria I, Granja M, Bueno C, Lopez-Tarruella S, Peinado P, Sotelo M, Jerez Y, Moreno F, Torres G, Lobo M, Marquez-Rodas I, Del Monte-Millan M, Mart\u00edn M, Garc\u00eda-Saenz JA (2017) Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Res Treat 162(1):181\u2013189. https:\/\/doi.org\/10.1007\/s10549-016-4098-z","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6387_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-016-3866-0","volume":"158","author":"SR Tiwari","year":"2016","unstructured":"Tiwari SR, Mishra P, Raska P, Calhoun B, Abraham J, Moore H, Budd GT, Fanning A, Valente S, Stewart R, Grobmyer SR, Montero AJ (2016) Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab\/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat 158(1):189\u2013193. https:\/\/doi.org\/10.1007\/s10549-016-3866-0","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6387_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/tbj.12927","volume":"24","author":"J Bayo","year":"2018","unstructured":"Bayo J, Avi\u00f1\u00f3 V, Toscano F, Jim\u00e9nez F (2018) Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis. Breast J 24(4):462\u2013467. https:\/\/doi.org\/10.1111\/tbj.12927","journal-title":"Breast J"},{"issue":"9","key":"6387_CR37","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.6004\/jnccn.2017.7010","volume":"15","author":"YL Li","year":"2017","unstructured":"Li YL, Family L, Yang SJ, Klippel Z, Page JH, Chao C (2017) Risk of febrile neutropenia associated with select myelosuppressive chemotherapy regimens in a large community-based oncology practice. J Natl Compr Canc Netw 15(9):1122\u20131130. https:\/\/doi.org\/10.6004\/jnccn.2017.7010","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"6387_CR38","doi-asserted-by":"publisher","first-page":"e1181","DOI":"10.1016\/j.clbc.2018.04.016","volume":"18","author":"R Ladwa","year":"2018","unstructured":"Ladwa R, Kalas T, Pathmanathan S, Woodward N, Wyld D, Sanmugarajah J (2018) Maintaining dose intensity of adjuvant chemotherapy in older patients with breast cancer. Clin Breast Cancer 18(5):e1181\u2013e1187. https:\/\/doi.org\/10.1016\/j.clbc.2018.04.016","journal-title":"Clin Breast Cancer"},{"key":"6387_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-05111-6","author":"CF Lee","year":"2019","unstructured":"Lee CF, Zhou K, Young WM, Wong CS, Ng TY, Lee SF, Leung K, Wong LKM, So KH, Tang W, Chong G, Chan SK, Yip YTE, Ma VYM, Yeung A, Chin CHY, Kwan MW, Tsang HT (2019) Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: a retrospective cohort study on duration of prophylactic GCSF administration. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-019-05111-6","journal-title":"Support Care Cancer"},{"issue":"5","key":"6387_CR40","doi-asserted-by":"publisher","first-page":"e1266","DOI":"10.1002\/cnr2.1266","volume":"3","author":"SJ Zardawi","year":"2020","unstructured":"Zardawi SJ, Nordman I, Zdenkowski N (2020) A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens. Cancer Rep (Hoboken) 3(5):e1266. https:\/\/doi.org\/10.1002\/cnr2.1266","journal-title":"Cancer Rep (Hoboken)"},{"issue":"4","key":"6387_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/xeb.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR (2018) A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc 16(4):195\u2013203. https:\/\/doi.org\/10.1097\/xeb.0000000000000141","journal-title":"Int J Evid Based Healthc"},{"key":"6387_CR42","unstructured":"Genentech\/Roche FH (2017) Perjeta: Summary of Product Characteristics (Annex I). European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/perjeta-epar-product-information_en.pdf. Accessed 27 Oct 2020"},{"issue":"2","key":"6387_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"issue":"1","key":"6387_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25\u201332. https:\/\/doi.org\/10.1016\/s1470-2045(11)70336-9","journal-title":"Lancet Oncol"},{"issue":"10","key":"6387_CR45","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00520-011-1375-6","volume":"20","author":"T Younis","year":"2012","unstructured":"Younis T, Rayson D, Thompson K (2012) Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer 20(10):2523\u20132530. https:\/\/doi.org\/10.1007\/s00520-011-1375-6","journal-title":"Support Care Cancer"},{"issue":"3","key":"6387_CR46","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-015-3531-z","volume":"153","author":"T Do","year":"2015","unstructured":"Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV (2015) The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat 153(3):591\u2013597. https:\/\/doi.org\/10.1007\/s10549-015-3531-z","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06387-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T16:12:09Z","timestamp":1635696729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06387-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6387"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06387-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"26 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SAH: Contracted research funding paid to institution: Ambrx, Amgen,\u00a0Astra Zeneca,\u00a0Arvinas, Bayer, Daiichi-Sankyo, Genentech\/Roche,\u00a0Gilead,\u00a0GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd.; Travel support: Lilly (2019); Stock options: NK Max. HW: Institutional financial interest: consulting fees and honoraria to his institute from AstraZeneca, Biocartis, Lilly, Novartis, Pfizer, PUMA Biotechnology, Roche, Sirtex, Daiiji. Unrestricted research grants to his institute from Roche and Novartis. Travel support: Roche and Pfizer. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Education-Support Committee (OBC) of the KU\/UZ Leuven consented to the launch of this study. It judged that this study consisted in a pure literature study, and that this type of research does not require approval from a committee for medical ethics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}